# A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Study · id `cardio:ct-nct07783802` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07783802](<https://clinicaltrials.gov/study/NCT07783802>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07783802

Browse, organ or system: Blood vessels; Kidneys; Metabolism  
Browse, condition area: High blood pressure; Coronary and vascular disease; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07783802. Randomized; double masking; primary purpose treatment. Start 2026-08-27 (actual); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07783802, source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)
- Started: 2026-08-27 (actual) (ClinicalTrials.gov record NCT07783802, source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT07783802, source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07783802, source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Argentina; Japan; Puerto Rico (ClinicalTrials.gov record NCT07783802, source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07783802-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Acronym: CLARITY-CRP
- Condition: Atherosclerosis
- Condition: Cardiovascular Disease
- Condition: Obesity
- Condition: Hypertension
- Condition: Diabetes Mellitus, Type 2
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Clazakizumab
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 57f8eaa224e72767b4f0a3c2bd10277df7ef06451065bc7848884195ff6eeca3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
